康俄

Kange (Shanghai) Medical Technology is a clinical-stage biotechnology company dedicated to advancing photodynamic therapy (PDT) for oncology and precancerous conditions. Headquartered in the Pudong-Russia (Pu-E) incubator in Shanghai, the company focuses on the development and commercialization of second-generation photosensitizers, leveraging established Russian medical expertise. Its lead candidate, Chlorin e6 tris-meglumine salt for injection, is a modified chemical drug (Class 2.1) currently undergoing clinical trials for indications including high-grade squamous intraepithelial lesion (HSIL) of the cervix and adult lymphocytic leukemia. Kange's proprietary platform specializes in the purification and formulation of chlorin-based compounds to optimize light-activated therapeutic efficacy. The company aims to provide innovative, minimally invasive solutions for patients with unmet medical needs in the field of photodynamic medicine.